Active Ingredient History
Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug that was first approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects; it was never approved in the United States. Rimonabant is an inverse agonist for the cannabinoid receptor CB1 and was the first drug approved in that class. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Albuminuria (Phase 3)
Alcohol Drinking (Phase 2)
Arteriosclerosis (Phase 3)
Atherosclerosis (Phase 4)
Cannabis (Phase 2)
Cardiovascular Diseases (Phase 4)
Carotid Stenosis (Phase 3)
Cigarette Smoking (Phase 3)
Coronary Artery Disease (Phase 3)
Diabetes Mellitus, Type 2 (Phase 3)
Dyslipidemias (Phase 3)
Fatty Liver (Phase 3)
Feeding and Eating Disorders (Phase 3)
Healthy Volunteers (Phase 2)
Hypertension (Phase 2)
Marijuana Abuse (Phase 2)
Metabolic Syndrome (Phase 3)
Obesity (Phase 4)
Pain (Phase 1)
Prader-Willi Syndrome (Phase 3)
Prediabetic State (Phase 3)
Psychotic Disorders (Phase 2)
Schizophrenia (Phase 2)
Smoking (Phase 2)
Smoking Cessation (Phase 3)
Weight Loss (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue